PT1237551E - Formulacoes farmaceuticas contendo zolmitriptano - Google Patents

Formulacoes farmaceuticas contendo zolmitriptano

Info

Publication number
PT1237551E
PT1237551E PT00979765T PT00979765T PT1237551E PT 1237551 E PT1237551 E PT 1237551E PT 00979765 T PT00979765 T PT 00979765T PT 00979765 T PT00979765 T PT 00979765T PT 1237551 E PT1237551 E PT 1237551E
Authority
PT
Portugal
Prior art keywords
pharmaceutical formulations
formulations containing
zolmitriptan
containing zolmitriptan
formulation
Prior art date
Application number
PT00979765T
Other languages
English (en)
Portuguese (pt)
Inventor
Dearn Alan Roy
Williamson Sarah Louise
Summers Simon John
Coomber Trevor John
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10865629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1237551(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1237551E publication Critical patent/PT1237551E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT00979765T 1999-12-03 2000-11-28 Formulacoes farmaceuticas contendo zolmitriptano PT1237551E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9928578.5A GB9928578D0 (en) 1999-12-03 1999-12-03 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
PT1237551E true PT1237551E (pt) 2005-07-29

Family

ID=10865629

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00979765T PT1237551E (pt) 1999-12-03 2000-11-28 Formulacoes farmaceuticas contendo zolmitriptano

Country Status (28)

Country Link
US (2) US6750237B1 (enExample)
EP (1) EP1237551B1 (enExample)
JP (1) JP2003515559A (enExample)
KR (1) KR100670092B1 (enExample)
CN (1) CN1222287C (enExample)
AT (1) ATE291914T1 (enExample)
AU (1) AU778092B2 (enExample)
BR (1) BRPI0016138B8 (enExample)
CA (1) CA2392050C (enExample)
CZ (1) CZ301528B6 (enExample)
DE (1) DE60019162T2 (enExample)
EE (1) EE05305B1 (enExample)
ES (1) ES2236001T3 (enExample)
GB (2) GB9928578D0 (enExample)
HK (2) HK1048445B (enExample)
HU (1) HU229458B1 (enExample)
IL (2) IL149578A0 (enExample)
IS (1) IS2135B (enExample)
MX (1) MXPA02005319A (enExample)
NO (1) NO322119B1 (enExample)
NZ (1) NZ518862A (enExample)
PL (1) PL200679B1 (enExample)
PT (1) PT1237551E (enExample)
RU (1) RU2255736C2 (enExample)
SK (1) SK287228B6 (enExample)
UA (1) UA75059C2 (enExample)
WO (1) WO2001039772A1 (enExample)
ZA (1) ZA200203704B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
WO2005115360A2 (en) * 2004-05-11 2005-12-08 Becton, Dickinson And Company Formulations of anti-pain agents and methods of using the same
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP3216445A1 (en) * 2004-05-28 2017-09-13 Imaginot Pty Ltd. Oral therapeutic compound delivery system
EP1812428A2 (en) * 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan crystal forms
CN100341504C (zh) * 2004-12-01 2007-10-10 鲁南制药集团股份有限公司 佐米曲普坦速释制剂
EP3263117A1 (en) * 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
DE602007013440D1 (de) * 2006-10-19 2011-05-05 Auspex Pharmaceuticals Inc Substituierte indole
KR101517415B1 (ko) * 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
US9186359B2 (en) 2010-10-15 2015-11-17 Contera Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
JP6121734B2 (ja) * 2012-02-09 2017-04-26 久光製薬株式会社 マイクロニードル用ゾルミトリプタン含有コーティング組成物及びマイクロニードルデバイス
PT2838517T (pt) 2012-04-18 2018-01-04 Contera Pharma Aps Formulação farmacêutica disponível sob forma oral adequada para a melhoria da gestão dos distúrbios da mobilidade
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
KR101624049B1 (ko) 2014-10-29 2016-05-24 연세대학교 산학협력단 사카린을 이용한 용해도를 증가시킨 약제학적 조성물
CN108135916B (zh) * 2015-06-19 2022-01-28 北京科辉智药生物科技有限责任公司 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用
WO2017122161A1 (en) 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
JP7227896B2 (ja) 2016-07-11 2023-02-22 コンテラ ファーマ エー／エス 朝の無動状態を治療するための拍動性薬物送達系
WO2019126766A1 (en) * 2017-12-21 2019-06-27 Taiwan Liposome Co., Ltd. Sustained-release triptan compositions and method of use the same through subdermal route or the like
US20210322343A1 (en) 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69132691T2 (de) 1990-06-07 2002-06-20 Astrazeneca Ab, Soedertaelje Indolderivate als 5-HT1-like Agonisten
GB9012672D0 (en) * 1990-06-07 1990-08-01 Wellcome Found Therapeutic heterocyclic compounds
GB9516145D0 (en) * 1995-08-07 1995-10-04 Wellcome Found Improved chemical synthesis
JP2000505090A (ja) * 1996-07-11 2000-04-25 ファーマーク、ニーダーランド、ベスローテン、フェンノートシャップ インドール選択的セロトニンアゴニストを含む包接錯体
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
AU718967B2 (en) 1997-02-05 2000-05-04 Jagotec Ag Medical aerosol formulations
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
GB2373726B (en) 2004-10-20
CA2392050A1 (en) 2001-06-07
WO2001039772A1 (en) 2001-06-07
PL200679B1 (pl) 2009-01-30
US6750237B1 (en) 2004-06-15
HK1048445B (en) 2005-08-26
AU1715701A (en) 2001-06-12
EE200200283A (et) 2003-06-16
GB0214845D0 (en) 2002-08-07
NO322119B1 (no) 2006-08-14
EP1237551A1 (en) 2002-09-11
IL149578A (en) 2008-04-13
EE05305B1 (et) 2010-06-15
CN1402636A (zh) 2003-03-12
SK7532002A3 (en) 2002-12-03
IS6394A (is) 2002-05-24
NZ518862A (en) 2004-02-27
CZ20021901A3 (cs) 2002-11-13
US7220767B2 (en) 2007-05-22
NO20022525L (no) 2002-05-28
HU229458B1 (en) 2013-12-30
IS2135B (is) 2006-08-15
CZ301528B6 (cs) 2010-04-07
KR100670092B1 (ko) 2007-01-17
HUP0203597A3 (en) 2005-07-28
BR0016138A (pt) 2002-08-06
GB9928578D0 (en) 2000-02-02
HK1048445A1 (en) 2003-04-04
ES2236001T3 (es) 2005-07-16
KR20020058051A (ko) 2002-07-12
UA75059C2 (uk) 2006-03-15
RU2255736C2 (ru) 2005-07-10
EP1237551B1 (en) 2005-03-30
AU778092B2 (en) 2004-11-18
DE60019162T2 (de) 2006-02-02
HUP0203597A2 (hu) 2003-02-28
ATE291914T1 (de) 2005-04-15
CA2392050C (en) 2009-11-24
ZA200203704B (en) 2003-10-29
RU2002117649A (ru) 2004-01-27
IL149578A0 (en) 2002-11-10
GB2373726A (en) 2002-10-02
BR0016138B1 (pt) 2013-09-10
HK1048442B (zh) 2005-05-13
HK1048442A1 (en) 2003-04-04
CN1222287C (zh) 2005-10-12
US20040214899A1 (en) 2004-10-28
NO20022525D0 (no) 2002-05-28
BRPI0016138B8 (pt) 2021-05-25
PL357597A1 (en) 2004-07-26
DE60019162D1 (de) 2005-05-04
HK1053430A1 (en) 2003-10-24
SK287228B6 (sk) 2010-03-08
JP2003515559A (ja) 2003-05-07
MXPA02005319A (es) 2002-12-06

Similar Documents

Publication Publication Date Title
PT1237551E (pt) Formulacoes farmaceuticas contendo zolmitriptano
GB0005251D0 (en) Therapeutic compounds
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
ID27504A (id) Formulasi oral baru
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
ATE376832T1 (de) Verzögert freisetzende formulierungen von oxymorphon
HUP0301349A2 (hu) IL-11-tartalmú készítmények
SE9802208D0 (sv) Novel compounds
NO20004419D0 (no) Ny anvendelse
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DE60019334D1 (de) Antivirale arznei
YU16399A (sh) ) UPOTREBA INHIBITOR H +, K+ - ATP- aze I FARMACEUTSKA FORMULACIJA ZA SIMULTANU, SEPARATNU ILI SEKVENCIJALNU UPOTREBU, KOJA SADRZI INHIBITOR H +, K+-ATP- aze I GLUKOKORTIKOID INHIBITOR H +, K+- ATP- aze
SE0001916D0 (sv) Novel formulation
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
SE9504662D0 (sv) New compounds
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
SE9604752D0 (sv) Formulation and use
ES2159479A1 (es) Nuevos indazoles como inhibidores de la ciclooxigenasa-ii
TR200000916T2 (tr) İkameli piperidin türevleri.
DE60004819D1 (de) 10-formyltetrahydrofolate dehydrogenase als therapeutischen mittel
SE9802207D0 (sv) Novel compounds
UA38889A (uk) Лікувальний засіб "ліварекс" на основі диметоксіуреїдофосфорної кислоти